MedTrace Logo

A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone

NCT00240006 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 307

Last updated 2011-04-11

No results posted yet for this study

Summary

To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions® and their MS Center versus those who receive support only from Shared Solutions®.

Conditions

Interventions

PROCEDURE

Shared Solutions® plus MS Center v. Shared Solutions®

Copaxone

Sponsors & Collaborators

  • Teva Neuroscience, Inc.

    lead INDUSTRY

Principal Investigators

  • MerriKay Oleen-Burkey, Ph.D. · Teva Neuroscience, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-01-31
Completion
2007-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240006 on ClinicalTrials.gov